Skip to main content
. 2024 May 15;110(9):5545–5562. doi: 10.1097/JS9.0000000000001650

Table 6.

The baseline characteristics of the patients in the training and validation groups were compared.

Variable Classification Training Validation P
Sex Male 497 (80.3%) 134 (74%) 0.07
Female 122 (19.7%) 47 (26%)
Miss 0 0
Age 48.47±19.676 49.51±18.5 0.527
Miss 0 0
Hypertension Y 156 (25.2%) 47 (26%) 0.835
N 463 (74.8%) 134 (74%)
Miss 0 0
Pupil Unequal 221 (35.7%) 73 (40.3%) 0.256
Equal 398 (64.3%) 108 (59.7%)
Miss 0 0
SAH Y 392 (63.3%) 117 (64.6%) 0.766
N 226 (36.5%) 64 (35.4%)
Miss 1 0
Brain herniation Y 239 (38.6%) 71 (39.2%) 0.881
N 380 (61.4%) 110 (60.8%)
Miss 0 0
CI Y 34 (5.5%) 6 (3.3%) 0.235
N 584 (94.3%) 175 (96.7%)
Miss 1 0
WBC 16.135 (12.015–20.5275) 16.205 (11.99–20.945) 0.974
Miss 5 1
NEU 13.715 (9.8175–18.145) 13.66 (10.155–18.1025) 0.93
Miss 5 1
LYM 1.21 (0.85–1.84) 1.14 (0.82–1.7975) 0.451
Miss 5 1
MON 0.63 (0.38–0.92) 0.63 (0.4–0.9475) 0.593
Miss 5 1
MCV 89.4 (86.4–92.5) 89.3 (86.6–92.05) 0.697
Miss 5 1
MCH 30.3 (29.2–31.6) 30.4 (29.4–31.375) 0.741
Miss 5 1
CR 72 (59.5–90) 74 (61.25–87) 0.779
Miss 6 1
GLU 8.8 (6.98–11.45) 9.17 (7.125–12.1075) 0.219
Miss 6 1
TP 67 (59.9–73) 66.15 (58.525–73) 0.494
Miss 8 3
ALB 40 (36–43.6) 39.9 (34.825–44) 0.352
Miss 8 3
GLB 24.5 (20.8–29.075) 24.1 (20.375–28.825) 0.387
Miss 255 77
CK 367 (174–756) 348.5 (191.5–803) 0.682
Miss 30 11
CK-MB 27 (17–51) 33.4 (17–59.25) 0.082
Miss 30 11
K 3.81 (3.5–4.2) 3.8 (3.343–4.1) 0.127
Miss 6 1
Na 138.8 (136–142) 139 (136.525–141.1) 0.697
Miss 6 1
Ca 2.13 (2.02–2.24) 2.14 (2.01–2.2375) 0.916
Miss 6 1
FDP 86.7 (27.25–152.0425) 119.8 (26.225–154.425) 0.596
Miss 87 27
D-Dimer 24.14 (7.48–35.2) 25.855 (6.67–35.2) 0.728
Miss 28 9
PT 12.1 (11.4–13.2) 12 (11.4–13.1) 0.799
Miss 25 7
TT 18 (16.5–19.9) 18.15 (16.4–20.125) 0.584
Miss 25 7
FIB 2.04 (1.46–2.995) 1.995 (1.5075–3.095) 0.944
Miss 25 7
CRP 12.85 (7.2–47.325) 18.75 (7.2–62.775) 0.094
Miss 65 13
Miss 25 7
SDH High (≥14.05) 387 (62.5%) 107 (59.1%) 0.407
Low (<14.05) 226 (36.5%) 74 (40.9%)
Miss 0 0
Coagulopathy Y 438 (70.8%) 138 (76.2%) 0.17
N 171 (27.6%) 41 (22.7%)
Miss 10 2
X1 1point 298 (48.1%) 87 (48.1%) 0.347
2 points 82 (13.2%) 18 (9.9%)
3 points 140 (22.6%) 51 (28.2%)
4 points 89 (14.4%) 23 (12.7%)
Miss 10 2

ALB, albumin; APTT, activated partial thromboplastin time; CI, cerebral ischemic; CK, creatine kinase; CK-MB, creatine kinase isoenzyme; Cr, creatinine; CRP, C-reactive protein; FDP, fibrin degradation products; FIB, Fibrinogen; GLB, globulin; Glu, glucose; INR, International Normalized Ratio; LYM, lymphocyte; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume; MON, monocyte; NEU, neutrophile; PT, Prothrombin time; SAH, subarachnoid hemorrhage; SDH, subdural hematoma; TP, total protein; TT, thrombin time; WBC, white blood cell; X1 (1 point), patients with coagulopathy and thick SDH thickness; X1 (2 points), patients with coagulopathy and thin SDH thickness; X1 (3 points), patients without coagulopathy and with thick SDH thickness; X1 (4 points), patients without coagulopathy and with thin SDH thickness; X1, coagulopathy combined with subdural hematoma thickness.

All data were analyzed using the chi-square test, rank-sum test, and Fisher’s precision probability test, and P<0.05 was considered to indicate statistically significant differences.